Hyaluronic Acid Herbal Extract
GET A QUOTE REQUEST MSDS
Get A Quote
List
1

Popular searches

Recommended products

Guanidine Carbonate
050-000-001 Dihydromyricetin
050-000-207 Triptolide
020-000-118 Micro Hyaluronic Acid (Micro HA), Super Active
020-000-275 Methacrylated Hyaluronic Acid (HAMA)
  • Home
  • Pharmaceuticals
  • (Discontinued) 040-000-310 Abiraterone Acetate CAS 154229-18-2

    • SKIP TO

    (Discontinued) 040-000-310 Abiraterone Acetate CAS 154229-18-2

    (0)
    Write a review

    About This Item

    Catalog No.
    040-000-310

    Discontinued

    Synonyms Abiraterone
    Keywords metastatic castration-resistant prostate cancer
    Related products Red clover extract,  Viagra (Sildenafil Citrate) Powder

    Quantity

    kg
    Inquiry Add to cart

    Technical Service

    Need help? Our team of experienced scientists is here for you.
    Contact us

    Description

    Abiraterone Acetate Specifications


    Product Name Abiraterone Acetate
    CAS Registry Number 154229-18-2
    Molecular Formula C26H33NO2
    Molecular Weight 391.55 g/mol
    Purity >99.0 %
    Appearance White powder
    Package 1kg-25kg
    Shelf life 2 years
    Functions Treatment of mCSPC

    Abiraterone Acetate Description:


    Abiraterone Acetate is a CYP17 inhibitor, suitable for use in combination with prednisone for the treatment of patients with metastatic castration-refractory prostate cancer who have previously received docetaxel-containing chemotherapy.

    ZYTIGA (abiraterone acetate) is a prescription medicine that is used along with prednisone. ZYTIGA is used to treat men with prostate cancer that has spread to other parts of the body.

    abiraterone acetate

    Abiraterone Acetate Applications:


    Abiraterone Acetate is used in combination with prednisone, a corticosteroid, as a treatment for mCRPC (previously called hormone-resistant or hormone-refractory prostate cancer).

    Reference:


    1. O'Donnell, A., Judson, I., Dowsett, M., et al. Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. British Journal of Cancer 90(12), 2317-2325 (2004).
    2. Ryan, C.J., Smith, M.R., de Bono, J.S., et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. New England Journal of Medicine 368(2), 138-148 (2013).
    3. Potter, G.A., Barrie, S.E., Jarman, M., et al. Novel steroidal inhibitors of human cytochrome P45017α (17α-hydroxylase-C17,20-lyase): Potential agents for the treatment of prostatic cancer. Journal of Medicinal Chemistry 38(13), 2463-2471 (1995).

     

    Reviews

    5 Stars
    2
    4 Stars
    0
    3 Stars
    0
    2 Stars
    0
    1 Stars
    0
    Write a review

    Related Products

    Guanidine Carbonate
    Inquiry Add to List
    Sumatriptan Succinate
    Inquiry Add to List
    Allantoin
    Inquiry Add to List
    (R)-Amino-(4-hydroxyphenyl)acetic acid methyl ester hydrochloride
    Inquiry Add to List
    D(-)-4-Hydroxyphenylglycine
    Inquiry Add to List
    Potassium (R)-[(3-ethoxy-1-methyl-3-oxoprop-1-enyl)amino]phenylacetate
    Inquiry Add to List

    Write a Review

    Name
    E-mail
    Rating
    Review

    Get a Quote

    Send us an inquiry now to find out more information and the latest prices, thanks!
    Product Name
    Quantity
    Name
    Email
    Phone
    Company
    Application
    Country
    United States
    • United States
    • Afghanistan
    • Aland Islands
    • Albania
    • Algeria
    • American Samoa
    • Andorra
    • Angola
    • Anguilla
    • Antarctica
    • Antigua and Barbuda
    • Argentina
    • Armenia
    • Aruba
    • Australia
    • Austria
    • Azerbaijan
    • Bahamas
    • Bahrain
    • Bangladesh
    • Barbados
    • Belarus
    • Belgium
    • Belize
    • Benin
    • Bermuda
    • Bhutan
    • Bolivia
    • Bosnia and Herzegovina
    • Botswana
    • Bouvet Island
    • Brazil
    • British Indian Ocean Territory
    • British Virgin Islands
    • Brunei
    • Bulgaria
    • Burkina Faso
    • Burundi
    • Cambodia
    • Cameroon
    • Canada
    • Cape Verde
    • Cayman Islands
    • Central African Republic
    • Chad
    • Chile
    • China
    • Christmas Island
    • Cocos (Keeling) Islands
    • Colombia
    • Comoros
    • Congo
    • Cook Islands
    • Costa Rica
    • Croatia
    • Cuba
    • Cyprus
    • Czech Republic
    • Democratic Republic of Congo
    • Denmark
    • Disputed Territory
    • Djibouti
    • Dominica
    • Dominican Republic
    • East Timor
    • Ecuador
    • Egypt
    • El Salvador
    • Equatorial Guinea
    • Eritrea
    • Estonia
    • Ethiopia
    • Falkland Islands
    • Faroe Islands
    • Federated States of Micronesia
    • Fiji
    • Finland
    • France
    • French Guyana
    • French Polynesia
    • French Southern Territories
    • Gabon
    • Gambia
    • Georgia
    • Germany
    • Ghana
    • Gibraltar
    • Greece
    • Greenland
    • Grenada
    • Guadeloupe
    • Guam
    • Guatemala
    • Guinea
    • Guinea-Bissau
    • Guyana
    • Haiti
    • Heard Island and Mcdonald Islands
    • Honduras
    • Hong Kong
    • Hungary
    • Iceland
    • India
    • Indonesia
    • Iran
    • Iraq
    • Iraq-Saudi Arabia Neutral Zone
    • Ireland
    • Israel
    • Italy
    • Ivory Coast
    • Jamaica
    • Japan
    • Jordan
    • Kazakhstan
    • Kenya
    • Kiribati
    • Kuwait
    • Kyrgyzstan
    • Laos
    • Latvia
    • Lebanon
    • Lesotho
    • Liberia
    • Libya
    • Liechtenstein
    • Lithuania
    • Luxembourg
    • Macau
    • Macedonia
    • Madagascar
    • Malawi
    • Malaysia
    • Maldives
    • Mali
    • Malta
    • Marshall Islands
    • Martinique
    • Mauritania
    • Mauritius
    • Mayotte
    • Mexico
    • Moldova
    • Monaco
    • Mongolia
    • Montenegro
    • Montserrat
    • Morocco
    • Mozambique
    • Myanmar
    • Namibia
    • Nauru
    • Nepal
    • Netherlands Antilles
    • Netherlands
    • New Caledonia
    • New Zealand
    • Nicaragua
    • Niger
    • Nigeria
    • Niue
    • Norfolk Island
    • North Korea
    • Northern Mariana Islands
    • Norway
    • Oman
    • Pakistan
    • Palau
    • Palestinian Territories
    • Panama
    • Papua New Guinea
    • Paraguay
    • Peru
    • Philippines
    • Pitcairn Islands
    • Poland
    • Portugal
    • Puerto Rico
    • Qatar
    • Reunion
    • Romania
    • Russia
    • Rwanda
    • Saint Helena and Dependencies
    • Saint Kitts and Nevis
    • Saint Lucia
    • Saint Pierre and Miquelon
    • Saint Vincent and the Grenadines
    • Samoa
    • San Marino
    • Sao Tome and Principe
    • Saudi Arabia
    • Senegal
    • Serbia
    • Seychelles
    • Sierra Leone
    • Singapore
    • Slovakia
    • Slovenia
    • Solomon Islands
    • Somalia
    • South Africa
    • South Georgia and South Sandwich Islands
    • South Korea
    • Spain
    • Spratly Islands
    • Sri Lanka
    • Sudan
    • Suriname
    • Svalbard and Jan Mayen
    • Swaziland
    • Sweden
    • Switzerland
    • Syria
    • Taiwan
    • Tajikistan
    • Tanzania
    • Thailand
    • Togo
    • Tokelau
    • Tonga
    • Trinidad and Tobago
    • Tunisia
    • Turkey
    • Turkmenistan
    • Turks And Caicos Islands
    • Tuvalu
    • US Virgin Islands
    • Uganda
    • Ukraine
    • United Arab Emirates
    • United Kingdom
    • United States
    • United States Minor Outlying Islands
    • Uruguay
    • Uzbekistan
    • Vanuatu
    • Vatican City
    • Venezuela
    • Vietnam
    • Wallis and Futuna
    • Western Sahara
    • Yemen
    • Zambia
    • Zimbabwe
    Comments
    I would like to join the mailing list to receive updates from Stanford Chemicals.
    Check Code